Buprenorphine-naloxone microdosing

Marwah, Radhika; Coons, Caitlin; Myers, Jacqueline; Dumont, Zack

doi:10.46747/cfp.6612891

Cited by 6 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even more recently, microdosing strategies have been developed to help patients transition between full opioid agonists and buprenorphine/naloxone without going through withdrawal (e.g. Ahmed et al., 2021; Marwah et al., 2020; Sandhu et al., 2019). However, many questions remain concerning the ability of this therapeutic option to adequately control patients' pain.…”

Section: Discussionmentioning

confidence: 99%

The current state of knowledge on care for co‐occurring chronic pain and opioid use disorder: A scoping review

Archambault,

Bertrand,

Martel

et al. 2024

Journal of Clinical Nursing

View full text Add to dashboard Cite

Background and AimsOpioid use disorder often co‐occurs with chronic pain but assessment and treatment of these co‐occurring disorders is complex. This review aims to identify current treatments and delivery models for co‐occurring chronic pain and opioid use disorder (OUD) documented in the scientific literature.DesignScoping review.MethodsThe review was conducted in six databases in June 2022 (no time limit): CINAHL, PsycINFO, Web of Science, Cochrane, PubMed and Embase. The PRISMA‐ScR checklist was used to guide reporting.ResultsForty‐seven publications addressing the issue of co‐occurring chronic pain and OUD management were included. Randomized controlled trials provide evidence for the effectiveness of opioid agonist treatments (OAT) such as methadone or buprenorphine/naloxone, as well as for combining OAT with Mindfulness‐Oriented Recovery Enhancement or cognitive behavioural therapy. A number of other pharmacological treatments (opioid and nonopioid), nonpharmacological treatments (e.g. physiotherapy) and service delivery models (e.g. simultaneous treatment of comorbidities, interdisciplinary and interprofessional collaboration) are also underlined. In most cases, authors recommend a combination of strategies to meet patient needs.ConclusionsThe scoping review reveals gaps in evidence‐based knowledge to effectively care for co‐occurring chronic pain and OUD, but several experts recommend the uptake of known ‘best’ practices such as integrated treatment of the multiple biopsychosocial dimensions of the co‐occurring disorders as well as collaborative interdisciplinary work.Clinical RelevanceImproving services is dependent on alleviating barriers such as working in silos, the costs associated with nonpharmacological treatments, and the double stigma associated with pain in people with a substance use disorder.

show abstract

Section: Discussionmentioning

confidence: 99%

The current state of knowledge on care for co‐occurring chronic pain and opioid use disorder: A scoping review

Archambault,

Bertrand,

Martel

et al. 2024

Journal of Clinical Nursing

View full text Add to dashboard Cite

show abstract

“…Whereas buprenorphine is available for treatment of opioid use disorder in many countries, only a few have published reports of low dose buprenorphine initiations [12], none of which were from Israel. Since 2002, buprenorphine as part of MAT has been prescribed in Israel by doctors who have undergone a two day specialized training course and work in either public MAT centers or are private providers [13].…”

Section: Introductionmentioning

confidence: 99%